



SCIENTIFIC PROGRAMME

Sunday 19 September 2021

Health Professionals Programme

08:00 – 09:00

HP Kick-off meeting

Working Party Meeting

09:00 – 10:00

PReS Working Party Meeting 1 - VASCULITIS

Working Party Meeting

09:00 – 10:00

PReS Working Party Meeting 2 - IMAGING

Working Party Meeting

09:00 – 10:00

PReS Working Party Meeting 3 - SCLERODERMA

Plenary

10:00 – 10:45

Opening Ceremony Barbara Ansell Lecture by *Jane Burns (US)*

State-of-the-Art Blended Session

11:00 – 12:00

A year in review in clinical and basic science

11:00 – 11:30

A year in review in clinical science

Isabelle Kone-Paut (FR)

11:30 – 12:00

A year in review in basic science

Grant Schulert (US)

It is Sunday, take a break!

12:00 – 12:30

Industry Sponsored Symposium

12:45 – 13:45

Clinical and Practice Track

14:00 – 15:00

Comorbidities in juvenile rheumatic diseases

14:00 – 14:05

Patient perspective - Gastrointestinal (Coeliac and IBD), cardiovascular health, Psoriasis

Gudrun Baseler (DE)

14:05 – 14:25

Cardiovascular health in juvenile rheumatic diseases

Sarah Clarke (UK)

14:25 – 14:45

Gastroenterologist - IBD, coeliac and JIA
Sanja Kolacek (HR)

14:45 – 15:05

Dermatologist to speak about Psoriasis
Joy Wan (US)

ENCA/HP Programme

14:00 – 15:00

When there is more to cope with than the disease

14:00 – 14:17

The burden for the family of a child with a chronic rheumatic disease
Nathalie Billiard (AU)

14:17 – 14:34

Working with parents and families to support anxious children
Aimee Hildenbrand (US)

14:34 – 14:55

The additional challenges of autism in treating rheumatic disease
Marilène Strijbos (NL)

Clinical and Practice Track

14:00 – 15:00

Inflammation - new insights

14:00 – 14:20

Fibroblasts- their influence on inflammatory diseases
Chris Buckley (GB)

14:20 – 14:40

IFN homeostasis in the ER-Golgi axis
Marie Louise Fremont (FR)

14:40 – 15:00

New insights into CD8+ cells in autoimmunity
Femke van Wijk Utrecht (NL)

Basic and Translational Track

15:15 – 16:15

New techniques for treatments and discovery

15:15 – 15:35

How to detect cytokines in 2021?
Darragh Duffy (FR)

15:35 – 15:55

Phenotyping single cells: a new window into the immune system Sc technologies
Chryssie Brown (US)

15:55 – 16:15

Gene therapy in SAVI: CRISPR/CAS9 technology to cure pediatric inflammatory disease
Sebastien Viel (US)

ENCA Programme

Best Practice

15:15 – 16:15

Clinical and Practice Track

15:15 – 16:15

Case-based session

15:15 – 15:25

Difficult scleroderma case
Edoardo Marrani (IT)

15:25 – 15:35

Difficult scleroderma case – Expert

Kathryn Torok (US)

15:35 – 15:45

Difficult JDM case

Raquel Marquez (PT)

15 :45 – 15 :55

Difficult JDM case – Expert

Annet van Royen-Kerkhof (NL)

15:55- 16:05

Auto-immune encephalitis disease

Ezgi Deniz Batu (TR)

16 :05 – 16:15

Auto-immune encephalitis disease – Expert

Kumaran Deiva (FR)

Industry Sponsored Symposium

16 :30 – 17:30

Industry Sponsored Meet the Expert

17 :45 – 18:15

Monday 20 September 2021

Working Party Meeting

08:00 – 09:00

PReS Working Party Meeting 4 - LUPUS

Working Party Meeting

08:00 – 09:00

PReS Working Party Meeting 5 - VACCINATION

Side meeting

08:00 – 09:00

Global Task Force

State-of-the-Art Blended Session

09:00 – 09:45

Hypermobility Spectrum disorder syndrome in children: a joint challenge for HP

09:00 – 09:17

Children with hypermobility syndrome a multidisciplinary approach

Marion van Rossum (NL)

09:17 – 09:31

Training and patient education for children and youngsters with hypermobile joints and pain

Jane Simmonds (GB)

09:31 – 09:40

Internet exercise program for children with hypermobility syndrome

Kelly Robinson (IE)

Working Party Meeting

09:00 – 09:45

PReS Working Party Meeting 6 - UVEITIS

It is Monday, take a break!

09:45 – 10:15

Lightning talks 1: Autoinflammatory diseases, Disease outcome and transition, New diseases, Patient/parent organisation initiatives

10:15 – 11:15

10:15 – 10:22

O1 - Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: Results from the randomized phase 3 cluster trial

Jerold Jeyaratnam (NL)

10:22 – 10:29

O2 - Long-term safety of canakinumab in patients with autoinflammatory periodic fever syndromes interim analysis of the reliance registry

Jasmin B. Kuemmerle-Deschner (DE)

10:29 – 10:36

O3 - NLRP3 splice variants inactivate CAPS phenotype in vitro

Katerina Theodoropoulou (CH)

10:36 – 10:43

O4 - PGALSPLUS: A tool to facilitate the identification and assessment of children with serious musculoskeletal disease

Vicky Mercer (UK)

10:43 - 10:50

O5 - OAS1 GOF causes a novel autoinflammatory disease characterized by persistently elevated ifn signature, hypogammaglobulinemia, and alveolar proteinosis

Francesco Licciardi (IT)

10:50 – 10:57

O6 - While looking for one, you may find another: Tin soldiers and the search for undiagnosed individuals with Fibrodysplasia Ossificans Progressiva (FOP)

Christiaan Scott (ZA)

10:57 - 11:15

Discussion

Lightning talks 2: COVID-19 (Coronavirus), Immunodeficiency and infection related arthritis

10:15 – 11:15

10:15 – 10:22

O7 - Nailfold capillaroscopy: A sensitive method for evaluating microvascular involvement in children with SARS-COV-2 infection

Figen Çakmak (TR)

10:22 – 10:29

O8 - Outcomes of Covid-19 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases

Lianne Kearsley-Fleet (UK)

10:29 – 10:36

O9 - Benchmark analysis for congruencies and discrepancies of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis

Gülçin Otar Yener (TR)

10:36 – 10:43

O10 - SARS-COV2 antibody phenotype and immune gene expression in MIS-C

Kate Webb (ZA)

10:43 - 10:50

O11 - 22Q11.2 deletion (Di George) syndrome and chronic arthritis. An international case series of 21 cases

Rolando Cimaz (FR)

10:50 – 10:57

O12 - Clonally expanded peripheral t helper cells with distinct TCR VB repertoire characterize synovial inflammation in children with antibiotic-refractory Lyme arthritis

Johannes Dirks (DE)

10:57 - 11:15

Discussion

Lightning talks 3: Systemic lupus erythematosus and antiphospholipid syndrome

10:15 – 11:15

10:15 – 10:22

O19 - Disease-causing gene variants account for a minimum of 5.5% of juvenile-onset SLE patients in the UK

Amandine Charras (UK)

10:22 – 10:29

O20 - Induction therapy for pediatric onset lupus nephritis: Mycophenolate mofetil versus cyclophosphamide

Marwa Chbihi (FR)

10:29 – 10:36

O21 - Treatment of juvenile-onset systemic lupus erythematosus – “real world” data from the UK JSLE cohort study

Naomi Egbivwie (UK)

10:36 – 10:43

O22 - Excessive production of interferon- γ drives the expansion of T-BET+ B Cells in patients with systemic lupus erythematosus

Emiliano Marasco (IT)

10:43 - 10:50

O23 - Low disease activity state and clinical remission are achievable targets in JSLE, leading to a significant reduction in severe flare and new damage

Eve MD Smith (UK)

10:50 – 10:57

O24 - BCAP as a modulator of LPS-induced interferon production in relevance to the pathogenesis of systemic lupus erythematosus

Alessandra Tesser (IT)

10:57 - 11:15

Discussion

PRES General Assembly

11:30 – 13:00

Sponsored Symposium

13:15 – 14:15

Sponsored Symposium - Novartis

The Great Debate

14:30 – 15:30

IVIG vs Steroids as first line therapy in Kawasaki disease

Paul Brogan (GB)

Mary Beth Son (US)

Clinical and Practice Track

15:45 – 16:45

Consumer Engagement in Paediatric Rheumatology

15:45 – 16:05

How to win friends and influence people: strategies to agitate and advocate for the resourcing and support your service needs

Wendy Costello (IE)

16:05 – 16:25

'Building powerful patient-clinician partnerships – the Autoinflammatory Alliance story'

Karen Durrant (US)

HP Programme

15:45 – 16:45

Lower the barriers for physical activity from a multidimensional view

15:45 – 16:05

Psychological barriers for Physical activity

Johanna Lomholt (DK)

16:05 – 16:25

Its Teamwork - Encouraging parents and schools to promote PA for children with JIA

Kim Penne (IE)

16:25 – 16:45

Engaging young people in physical activity to help manage their arthritis

Sabrina Cavallo (CA)

Clinical and Practice Track

17:00 – 18:00

Digital Health Technologies

17:00 – 17:20

How social media will improve patient and population health in pediatric rheumatology

Jonathan Hausmann (US)

17:20 – 17:40

Empower, educate and connect: a patient's guide to the best online resources in paediatric rheumatic disease

Simon Stones (GB)

17:40 – 18:00

Telemedicine is here to stay: Virtual care and v-pGALS in paediatric rheumatology

Kristen Hayward (US)

HP Programme

17:00 – 18:00

Diverse perspectives on physical fitness outcome measurements

17:00 – 17:15

Measuring physical fitness in Northern Europe

Kristine Risum (NO)

17:15 – 17:30

Measuring physical fitness in Western Europe

Vic Harbottle (GB)

17:30 – 17:45

Measuring physical fitness in Northern America

Kristin Houghton (CA)

Basic and Translational Track

17:00 – 18:00

Genetic syndrome

17:00 – 17:20

LACC1-associated inflammation

Arthur Kaiser (GB)

17:20 – 17:40

ADA2 as a new endosomal DNA modifying hydrolase defining type 1 interferonopathy

Ole Kristian Grener-Tollersrud (NO)

17:40 – 18:00

Using Candida to treat CAPS: effect of beta glucan on NLRP3 inflammasome

Jessica Quintin (FR)

Industry Sponsored Symposium

18 :15 – 19:15

Industry Sponsored Meet the Expert

19 :30 – 20:00

Tuesday 21 September 2021

Clinical and Practice Track

08:00 – 09:00

Uveitis

08:00 – 08:05

Patient perspective

Catherine Wright (IE)

08:05 – 08:25

Ophthalmology perspective

Justine Smith (AU)

08:25 – 08:45

How to screen and treat children for uveitis - the rheumatologist perspective (new screening guidelines, e.g. recommendations for DMARD stop, new data on systemic treatments)

Gabriele Simonini (IT)

ENCA/HP Programme

08:00 – 09:00

Rare diseases and the implications for Health Professional management

08:00 – 08:21

Rare auto-inflammatory disease and the systemic implications for HP management

Veronique Hentgen (FR)

08:21 – 08:37

Children's voices of living with an autoinflammatory disease

Saskya Angevare (NL)

08:37 – 08:54

Health Professional approach to common problems in childhood familial Mediterranean fever

Nilay Arman (TR)

State-of-the-Art Blended Session

09:00 – 10:00

(JIA) New Drugs/New Perspectives

09:00 – 09:30

New agents in rheumatoid arthritis

John Issacs (UK)

09:30 – 10:00

New agents in AS

Dirk Elewaut (BE)

Clinical and Practice Track

10:15 – 11:15

Vasculitis with focus on ANCA-associated vasculitis and Takayasu (nephrology input) / most common vasculitis (IGA)

10:15 – 10:35

Takayasu arteritis (new angiographic classification scheme in TA)

Chris Scott (ZA)

10:35 – 10:55

IgA vasculitis - from immunopathogenesis to histologic classification - is it time for changes?

Marija Jelusic (HR)

10:55 – 11:15

cPAN (New recommendation for the treatment of cPAN/How to treat cPAN)

Seza Ozen (TR)

ENCA Programme

10:15 – 11:15

Industry Sponsored Symposium

11:30 – 10:30

PRINTO General Assembly

11:30 – 10:30

ENCA/HP: Round table discussion

11:30 – 10:30

Lightning talks 4: JIA (oligo, poly, psoriatic), Imaging, Psycho-social aspects and rehabilitation

12:45 – 13:45

12:45 – 12:52

O13 - Can musculoskeletal ultrasound and serum biomarkers predict disease flare in JIA patients in clinical remission?

Marta Mazzoni (IT)

12:52 – 12:59

O14 - Determinants of physician global assessment in juvenile idiopathic arthritis patients without active joints

Alessandra Alongi (IT)

12:59 – 13:06

O15 - Assessing the causal role of the human gut microbiome on JIA risk: A mendelian randomisation study

Sarah L Clarke (UK)

13:06 – 13:13

O16 - Twenty years experience with etanercept in treatment of juvenile idiopathic arthritis

Ariane Klein (DE)

13:13 – 13:20

O17 - Innovative methods for biomarker discovery in oligoarticular juvenile idiopathic arthritis

Federica Raggi (IT)

13:20 – 13:27

O18 - Psychiatric disorders in juvenile idiopathic arthritis - A population-based cohort study

Annacarin Horne (SE)

13:27 – 13:45

Discussion

Lightning talks 5: Macrophage activation syndrome and Systemic JIA

12:45 – 13:45

12:45 – 12:52

O25 - Mortality and clinical response to treatment in children with secondary hemophagocytic lymphohistiocytosis (SHLH)

Claudia Bracaglia (IT)

12:52 – 12:59

O26 - Activated CD8+ T cells discriminates patients with macrophage activation syndrome from patients with active systemic juvenile idiopathic arthritis

Giusi Prencipe (IT)

12:59 – 13:06

O27 - Development of clinical definitions of refractory disease trajectories in systemic JIA

Remco Erkens (NL)

13:06 – 13:13

O28 - Naive CD4+ T cell differentiation in systemic juvenile idiopathic arthritis is skewed towards a peripheral t helper cell phenotype

Julia Kuehn (DE)

13:13 – 13:20

O29 - Efficacy and safety of Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis in a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 study (JUNIPERA)

N Ruperto (IT)

13:20 – 13:27

O30 - Single-cell genomics reveals a shared monocyte interferon program in a subset of patients with systemic juvenile idiopathic arthritis, macrophage activation syndrome and lung disease

Emely Luise Verweyen (US)

13:27 – 13:45

Discussion

Lightning talks 6: Juvenile dermatomyositis, Scleroderma and related syndromes, Systemic lupus erythematosus and antiphospholipid syndrome, Uveitis

12:45 – 13:45

O31 - Investigating novel mechanisms of T cells in the pathogenesis of juvenile dermatomyositis

Lucy Rachel Marshall (UK)

O32 - Oxidised mitochondrial dna induces an interferon response in JDM: A new therapeutic target

Meredyth Wilkinson (UK)

O33 - Long-term follow-up of juvenile localized scleroderma patients treated with methotrexate-based standardized regimens (consensus treatment plans)

Suzanne Li (US)

O34 - Genetics of age at systemic lupus erythematosus diagnosis

Raffaella Carlomagno (CH)

O35 - Gene signature fingerprints divide SLE patients in subgroups with similar biological disease profiles: A multicenter longitudinal study

M. Javad Wahadat (NL)

O36 - Frequency of uveitis in craniofacial juvenile scleroderma

Maria Kirillovna Osminina (RU)

13:27 – 13:45

Discussion

The Great Debate

14:00 – 14:45

DMARD + TNF or sequential therapy

Randy Cron (US)

Petra Hissink Muller (NL)

Side meeting

14:00 – 15:00

Education Committee

Working Party Meeting

14:00 – 15:00

PRoS Working Party Meeting 7 - AUTOINFLAMMATORY

Industry Sponsored Meet the Expert

15:00 – 15:30

Working Party Meeting

15:45 - 16:45

PReS Working Party Meeting 8 – MAS

Working Party Meeting

15:45 - 16:45

PReS Working Party Meeting 9 - JDM

Side meeting

15:45 - 16:45

ERN/RITA

Plenary

16:45 – 17:15

Closing remarks & Awards presentation